
Home » Healthrageous, United BioSource, Boehringer Ingelheim launch SMART digital diabetes study
Healthrageous, United BioSource, Boehringer Ingelheim launch SMART digital diabetes study
July 19, 2013
Healthrageous, a digital health management company, and pharmaceutical company Boehringer Ingelheim have launched the SMART study with United BioSource (UBC) to evaluate a digital technology enabled self-management solution to potentially improve the health status of people with type 2 diabetes. The goal of the solution is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier for patients to self-manage their disease.
Through the Institutional Review Board (IRB) approved research project, adults who have been diagnosed with type 2 diabetes for at least six months will have access to Healthrageous’ digital diabetes self-management program. The web- and smartphone-delivered program will include a personalized action plan with health behavior improvement goals, a wireless glucose meter transmitting data to clinical monitors and HbA1c at-home test kits. By combining medical claims data, this collaboration will allow an evaluation of the impact a digital diabetes platform could have on medical and pharmaceutical costs, clinical care, consumer behavior modification and device and self-reported biometric health measures.
UBC will identify and help manage the recruitment of participants from nearly a dozen U.S. employers for the study.
“Through a patient-centric design, this study will allow us to collect and integrate patient-reported data, biometric data and claims data in order to generate new insights into health behaviors, outcomes and cost utilization,” said Abbe Steel, vice president, patient and physician services, UBC.
Upcoming Events
-
14Apr